Eli Lilly has added another piece to its growing direct-to-consumer health platform. The company announced a new partnership with smart ring maker Oura, giving LillyDirect users access to a free Oura Ring sizing kit and biometric tracking tools designed to complement GLP-1 treatment.
The timing is deliberate. Oura launched its GLP-1 Insights program just one month ago, a feature that helps patients on weight-loss drugs track how their body is responding over time. Lilly spotted the overlap and moved quickly. More than half of Oura’s members identify as having obesity or being overweight, and many of them were already logging their GLP-1 usage inside the app before any formal deal existed.
The partnership reflects a wider shift in how pharmaceutical companies are thinking about their relationship with patients. Selling a drug is no longer enough. Companies like Lilly are now building out the support infrastructure around the medicine, and wearables are a logical next step in that strategy.
What the Oura integration actually offers patients
The Oura Ring tracks a range of health metrics that are directly relevant to people managing their weight with GLP-1 medications:
- Sleep quality and duration
- Heart rate and heart rate variability
- Body temperature
- Daily activity levels
Jennifer Mazur, senior vice president of U.S. LillyDirect and consumer services at Lilly, says the goal is to give patients a clearer picture of their health beyond the number on a scale. “We’ve talked a lot about holistic support and this desire to go beyond the medicine to ensure people have access to quality education resources,” she said. “That was the impetus for this partnership with Oura.”
Patients can choose whether to share their biometric data with their healthcare provider. The option to share is there, but it is not required.
LillyDirect is growing fast
LillyDirect launched roughly two years ago with a relatively simple proposition: give patients a more direct way to access Lilly medications, often at lower cost. Since then, the platform has expanded significantly.
- More than 11 million prescription fills processed
- Approximately two million patients served
- LillyDirect accounted for 45% of new prescription volume for Lilly’s GLP-1 drugs since launch
- A partnership with Walmart now allows medication pickup at retail pharmacy locations
Mazur says the company has used this time to study where patients run into trouble. The friction points are not limited to getting a prescription. Patients also struggle to find the right medication, access it affordably, and understand how to use it once they have it.
Beyond medication: building a broader health platform
Lilly is positioning LillyDirect as more than a pharmacy channel. The platform already connects users with independent healthcare providers, behavioral health resources, and nutrition guidance. Importantly, Mazur notes that patients do not need a Lilly prescription to access these resources, including the Oura ring kit.
On the coverage side, Lilly is also actively building out support for its new weight-loss pill Foundayo, which includes a savings card for patients with commercial drug insurance and a self-pay option for those without. The company is also preparing for the Medicare GLP-1 Bridge program, a federal pilot that will give Medicare Part D patients access to certain GLP-1 drugs between July 2026 and December 2027.
Why this partnership makes sense for both companies
For Oura, the deal puts its hardware in front of millions of people who are actively managing a chronic condition and are likely to be engaged, long-term users. For Lilly, it adds a tangible, tech-forward benefit to LillyDirect that goes beyond price competition.
The collaboration also signals where the broader industry is heading. As GLP-1 drugs become more mainstream, the companies that build the most useful support ecosystem around them are likely to see stronger patient retention. A smart ring that helps someone understand their sleep and activity patterns is a low-friction way to keep them engaged with their health, and by extension, their treatment.
Mazur put it simply: the goal is to help patients take control “through the biometrics available to them at their fingertips.”